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Purpose: Individuals with cerebral palsy (CP) are at increased risk for frailty and chronic 
disease due to factors experienced throughout the lifespan, such as excessive sedentary behav-
iors and malnutrition. However, little is known about noncommunicable diseases (NCDs) and 
multimorbidity profiles in young adults with CP. The study objective was to compare NCD and 
multimorbidity profiles between young adults with and without CP.
Methods: A clinic-based sample of adults (18–30 years) with (n=452) and without (n=448) CP 
was examined at the University of Michigan Medical Center. The prevalence and predictors of 
13 NCDs were evaluated, including existing diagnoses or historical record of musculoskeletal, 
cardiometabolic, and pulmonary morbidities. The level of motor impairment was determined 
by the Gross Motor Function Classification System (GMFCS) and stratified by less vs more 
severe motor impairment (GMFCS I–III vs IV–V). Logistic regression was used to determine 
the odds of NCD morbidity and multimorbidity in adults with CP compared to adults without 
CP, and for GMFCS IV–V compared to GMFCS I–III in those with CP, after adjusting for age, 
sex, body mass index, and smoking.
Results: Adults with CP had a higher prevalence of osteopenia, osteoporosis, hypertension, myo-
cardial infarction, hyperlipidemia, asthma, and multimorbidity compared to adults without CP, and 
higher odds of musculoskeletal (odds ratio [OR]: 6.97) and cardiometabolic morbidity (OR: 1.98), 
and multimorbidity (OR: 2.67). Adults with CP with GMFCS levels IV–V had a higher prevalence 
of osteopenia/osteoporosis, osteoarthritis, hypertension, other cardiovascular conditions, pulmonary 
embolism, and multimorbidity, and higher odds of musculoskeletal (OR: 3.41), cardiometabolic (OR: 
2.05), pulmonary morbidity (OR: 1.42), and multimorbidity (OR: 3.45) compared to GMFCS I–III.
Conclusion: Young adults with CP have a higher prevalence of chronic NCDs and multimor-
bidity compared to young adults without CP, which is pronounced in those with more severe 
motor impairment. These findings reiterate the importance of early screening for prevention 
of NCDs in CP.
Keywords: cerebral palsy, noncommunicable disease, multimorbidity, osteoporosis, osteoar-
thritis, cardiovascular disease, diabetes, pulmonary disease
Introduction
Cerebral palsy (CP) results from damage to or malformation of the infant brain and 
is the most common physical disability in childhood.1 Children with CP present with 
impaired neuromuscular function,2–4 low levels of physical activity,5–7 poor cardiore-
spiratory fitness,8 underdeveloped musculoskeletal tissue,5,6 and a high degree of fat 
of total body9 and musculoskeletal5,6 depots, which are largely governed by the extent 
of motor impairment.5,6 Mobility decrements are common in children with CP as they 
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transition into and throughout adulthood.10–12 Consequently, 
individuals with CP may be at a heightened risk for develop-
ing chronic, noncommunicable diseases (NCDs) at younger 
ages compared to the general population.
There has been a considerable shift in the global burden 
of disease, with the prevalence of NCDs now outranking inju-
ries and communicable, maternal, neonatal, and nutritional 
disorders combined.13 The burden of NCDs has been climb-
ing with estimated costs of $7 trillion US dollars by 2030.14 
The adult CP population is steadily growing due to increases 
in survival rate15 and prevalence16 of CP in recent decades. 
Indeed, CP represents a significant lifetime disability for 
individuals, their families, and caregivers. CP is associated 
with increased prevalence of cardiometabolic mortality17 and 
morbidity,18,19 greatly reducing life expectancy,20 all of which 
may develop or be accelerated by the presence of impair-
ments and/or the aging process.18,19 There is, thus, strong 
rationale for approaching health care delivery for persons 
with CP within the context of a life course health development 
model.21 However, the framework that encompasses clinical 
care for patients with CP has been largely confined to issues 
that arise during childhood and adolescence, with little to 
no focus on understanding life course health development.
A comprehensive understanding of the primary and result-
ing sequela associated with aging in those with CP is lacking, 
especially in the early adult years. Better understanding these 
changes in health through the lifespan will help to guide future, 
target-specific preventive efforts in rehabilitation research and 
clinical practice to mitigate the exaggerated chronic conditions 
observed in patients with CP.19 The primary objective of this 
study was to examine the NCD profiles and risk factors in 
young adults with CP compared to young adults without CP. 
We hypothesized that young adults with CP would have a higher 
prevalence of NCDs compared to those without CP, and that risk 
factors would include obesity and greater motor impairments.
Patients and methods
Patient identification
A cohort query tool (Data Direct: https://datadirect.med.
umich.edu) was used to identify patients who had clini-
cal appointments at the University of Michigan Medical 
Center, as previously described.19 Briefly, we annotated the 
dataset using the Electronic Medical Records Search Engine 
(EMERSE) software. The EMERSE software is hosted 
behind the University of Michigan Medical Center firewall 
in a computing environment certified for storing protected 
health information. Access to EMERSE is limited to autho-
rized personnel who have patient data access privileges or, 
among those using it for research, have provided evidence of 
training in responsible research practices and proof of valid 
institutional review board (IRB) approvals, including demon-
stration of a need to review identifiable patient information.22 
At each login, users must complete a brief attestation form to 
document their intent of use. Audit trail logs are kept for each 
use session. The principal investigators (Peterson and Hurvitz) 
take full responsibility for de-identifying patient records and 
maintaining patient data confidentiality. The University of 
Michigan IRB approved this retrospective study, and patient 
consent to review their medical record was waived by the IRB 
because the nature of this study involved no more than mini-
mal risk to the subjects; the waiver did not adversely affect 
the rights and welfare of the subjects; the research could not 
practicably (ie, feasibly) be carried out without the waiver.
This internally developed web application provides an 
interface for searching electronic medical records with a 
bundle of word iterations and phrases for variables of inter-
est.22 Adults between 18 and 30 years of age, with a confirmed 
diagnosis of CP or no known neurological disorders (con-
trols), who had an encounter with University of Michigan 
Medicine between 01/01/2011 and 07/31/2017 (6.5-year 
period), were considered for this study. Among individuals 
with CP, the distribution of affected limbs (ie, quadriplegic, 
hemiplegic, diplegic) was obtained from medical records. 
The level of motor impairment was classified according to 
the Gross Motor Function Classification System (GMFCS). 
GMFCS ranks motor impairment with GMFCS I/II reflect-
ing gross motor independence, GMFCS III reflecting the use 
of assistive walking devices, and GMFCS IV–V reflecting 
wheelchair use for most to all mobility. We stratified GMFCS 
into two categories, GMFCS I–III and GMFCS IV–V, to 
reflect lesser and greater motor impairment, respectively.
Noncommunicable diseases
Clinical data were included for existing diagnosis or his-
torical record of various NCDs and were grouped into 
three categories, including 1) musculoskeletal morbidity: 
osteopenia and osteoporosis, osteoarthritis, and rheumatoid 
arthritis; 2) cardiometabolic morbidity: stroke, hypertension, 
other cardiovascular problems (eg, heart valve disorders, 
peripheral artery disease, aortic aneurysm, heart failure), 
coronary artery disease, impaired glucose tolerance or type 
2 diabetes, myocardial infarction, and hyperlipidemia (total 
cholesterol >240 mg/dL and/or triglyceride >200 mg/dL); 
and 3) pulmonary morbidity: asthma, pulmonary embolism, 
and emphysema. These conditions were chosen because of 
their potential impact on physical function and in accordance 
with the guidance from the literature relating to older adults 
and adults with disabilities.23,24




NCD and multimorbidity in young adults with CP
In addition to using the EMERSE, certain variables 
required additional data collection. For blood pressure, the 
most recent measurement was used to determine hypertension 
status (present vs absent) based on the Eighth Joint National 
Committee:25 systolic blood pressure ≥140 mmHg and/or 
diastolic blood pressure ≥90 mmHg. A clinical history of 
stroke and/or other cardiovascular problems (eg, heart valve 
disorders, peripheral artery disease, aortic aneurysm, heart 
failure) was included if it occurred at 18 years or older. 
Musculoskeletal, cardiometabolic, and pulmonary morbidi-
ties were defined on the basis of presence of at least one of 
the aforementioned chronic NCDs within each respective 
category. A morbidity score was created by summing the 
number of individual NCDs. Multimorbidity was defined 
as the presence of having at least two of the aforementioned 
NCDs.
Covariates
Demographic data, including race, age, and sex, were col-
lected using the EMERSE software. Body mass index (BMI) 
was calculated by dividing body mass by height squared 
(kg/m2). BMI was separated into underweight (<18.5), nor-
mal weight (18.5–24.9), overweight (25.0–29.9), and obese 
(≥30.0) categories. Smoking status was categorized as never 
vs current, occasional, or previous smoker.
Statistical analyses
Descriptive characteristics are provided as mean, standard 
deviation, and percentages. Participant demographics and 
NCD prevalence were compared between groups (young 
adults with vs without CP) and between the level of motor 
impairment for those with CP (GMFCS I–III vs IV–V) using 
two-sample t-tests and chi-square (χ2) tests for continuous 
and categorical measures, respectively. Multiple logistic 
regression was used to determine the odds of NCD morbidity 
categories (musculoskeletal, cardiometabolic, and pulmo-
nary) and multimorbidity, after adjusting for age, sex, race, 
BMI, and smoking status. The primary exposure of CP was 
included as a dichotomous indicator variable in all models. 
Data were analyzed using SAS software version 9.3 (SAS 
institute, Cary, NC, USA) with 2-sided 95% confidence 
intervals to determine significance.
Results
Descriptive characteristics
Descriptive characteristics of the study participants with 
(n=452) and without (n=448) CP are presented in Table 1. 
There were no group differences in age, sex, or obesity 
prevalence. However, there were group differences in race, 
underweight, normal weight, and overweight measures, and 
adults with CP had a lower prevalence of smoking status 
compared to adults without CP.
Of the young adults with CP, 231 (51%) were classified 
as GMFCS I–III and 221 (49%) as GMFCS IV–V (Table 2). 
There were no group differences in sex or race distribution. 
However, there were group differences in age, underweight, 
overweight, smoking status (GMFCS IV–V lower preva-
lence), and distribution of affected limbs in young adults with 
CP. A summary of morbidity score prevalence by CP status 
and GMFCS categories is depicted in Figure 1.
Table 1 Descriptive characteristics and NCD prevalence of 









Age (years), mean ± SD 23.7±2.8 23.6±3.4 0.74
Male, % 40.0 43.4 0.23
Race/ethnicity, %
Non-Hispanic White 73.7 81.2 0.01
Non-Hispanic Black 7.0 11.6 0.02
Hispanic or Mexican American 4.1 2.7 0.23
Unknown/other race 15.2 4.4 <0.001
BMI category, %
Underweight (BMI<18.5) 0.3 24.3 <0.001
Normal weight (BMI 18.5–24.9) 52.2 41.2 0.03
Overweight (BMI 25–29.9) 31.6 18.1 0.01
Obese (BMI≥30) 15.9 16.4 0.87
Smoking status, % 19.3 7.1 <0.001
Chronic NCD and multimorbidity prevalence, %
Musculoskeletal morbidity 7.5 44.9 <0.001
Osteopenia/osteoporosis 2.3 43.6 <0.001
Osteoarthritis 4.1 5.4 0.37
Rheumatoid arthritis 1.8 0.4 0.05
Cardiometabolic morbidity 8.4 20.6 <0.001
Stroke 0.0 0.0 n/a
Hypertension 3.2 11.8 <0.001
Other heart problems 4.1 5.3 0.38
Coronary artery disease 0.0 0.2 0.32
Diabetes 1.4 2.2 0.33
Myocardial infarction 0.0 2.0 0.01
Hyperlipidemia 1.1 3.0 0.04
Pulmonary morbidity 22.2 27.9 0.04
Asthma 21.4 27.0 0.03
Pulmonary embolism 0.9 1.8 0.25
Emphysema 0.0 1.0 0.05
Multimorbidity 7.2 24.3 <0.001
Abbreviations: BMI, body mass index; CP, cerebral palsy; NCD, noncommunicable 
disease; n/a, not applicable.






Adults with CP had a higher prevalence of osteopenia/osteo-
porosis compared to those without CP (Table 1). Adults with 
CP had a higher odds of musculoskeletal morbidity compared 
to those without CP (Table 3). Greater age, being under-
weight, and smoking status were all significantly associated 
with musculoskeletal morbidity.
Of the adults with CP, those with GMFCS IV–V had 
a higher prevalence of osteopenia/osteoporosis and osteo-
arthritis compared to those with GMFCS I–III (Table 2). 
Moreover, a higher prevalence of musculoskeletal morbidity 
was found for individuals with GMFCS levels IV–V (59.3%) 
as compared to those with GMFCS levels I–III (31.2%), as 
well as higher odds of musculoskeletal morbidity (odds ratio 
[OR]: 3.41; 95% CI: 2.18–5.35). Greater age (OR: 1.10; 
95% CI: 1.04–1.16) and underweight status (OR: 1.52; 95% 
CI: 1.02–1.27) were both associated with musculoskeletal 
morbidity in individuals with CP.
Cardiometabolic morbidity
Adults with CP had a higher prevalence of hypertension, 
myocardial infarction, and hyperlipidemia compared to those 
without CP (Table 1). Adults with CP had a higher odds of 
cardiometabolic morbidity compared to those without CP 
(Table 3), and only obesity was significantly associated with 
cardiometabolic morbidity.
Of the adults with CP, those with GMFCS IV–V had a 
higher prevalence of hypertension and other cardiovascular 
problems compared to those with GMFCS I–III (Table 2). 
Moreover, a higher prevalence of cardiometabolic morbid-
ity was found for individuals with GMFCS levels IV–V 
(26.2%) compared to GMFCS levels I–III (15.2%), as well 
as higher odds of cardiometabolic morbidity (OR: 2.05; 95% 
CI: 1.20–3.50). Only obesity (OR: 1.85; 95% CI: 1.01–3.41) 
was significantly associated with cardiometabolic morbidity 
in individuals with CP.
Pulmonary morbidity
Adults with CP had a higher prevalence of asthma compared 
to those without CP (Table 1). There were no group differ-
ences in the odds of pulmonary morbidity (Table 3), and only 
smoking status was significantly associated with pulmonary 
morbidity.
Of the adults with CP, those with GMFCS IV–V had 
a higher prevalence of pulmonary embolism compared to 
those with GMFCS I–III (Table 2). No difference in preva-
lence of pulmonary morbidity was found for individuals 
with GMFCS levels IV–V compared to GMFCS levels 
I–III; however, individuals with GMFCS levels IV–V had 
higher odds of pulmonary morbidity (OR: 1.42; 95% CI: 
1.02–1.80).
Multimorbidity
Adults with CP had a higher prevalence of multimorbidity 
compared to those without CP (Table 1), as well as a higher 
odds of multimorbidity compared to those without CP 
(Table 4). Underweight, obesity, and smoking status were 
all significantly associated with multimorbidity.
Table 2 Descriptive characteristics of young adults with cerebral 










Age (years), mean ± SD 23.0±3.2 24.3±3.5 0.01
Male, % 39.4 47.5 0.08
Race/ethnicity, %
Non-Hispanic White 84.4 77.9 0.09
Non-Hispanic Black 9.6 14.0 0.14
Hispanic or Mexican American 1.7 3.6 0.21
Unknown/other race 4.3 4.5 0.56
BMI category, %
Underweight (BMI<18.5) 10.8 38.5 <0.001
Normal weight (BMI 
18.5–24.9)
43.7 38.4 0.26
Overweight (BMI 25–29.9) 22.9 13.1 0.01
Obese (BMI≥30) 22.6 10.0 <0.001
Smoking status, % 10.4 3.8 0.01
Distribution, %
Quadriplegia 17.1 93.6 <0.001
Hemiplegia 38.7 1.9 <0.001
Diplegia 44.2 4.5 <0.001
Chronic NCD and multimorbidity prevalence, %
Musculoskeletal morbidity 31.2 59.3 <0.001
Osteopenia/osteoporosis 29.1 58.6 <0.001
Osteoarthritis 3.1 7.7 0.02
Rheumatoid arthritis 0.0 0.9 0.14
Cardiometabolic morbidity 15.2 26.2 <0.01
Stroke 0.0 0.0 n/a
Hypertension 9.1 15.0 0.04
Other heart problems 2.1 8.6 0.01
Coronary artery disease 0.0 0.5 0.31
Diabetes 1.7 2.7 0.47
Myocardial infarction 1.3 2.3 0.43
Hyperlipidemia 2.2 3.2 0.51
Pulmonary morbidity 25.5 30.3 0.26
Asthma 24.8 28.6 0.36
Pulmonary embolism 0.4 3.5 0.02
Emphysema 0.4 0.5 0.96
Multimorbidity 15.2 33.9 <0.001
Abbreviations: BMI, body mass index; GMFCS, Gross Motor Function 
Classification System; NCD, noncommunicable disease.




NCD and multimorbidity in young adults with CP
Of the adults with CP, adults with GMFCS IV–V had a 
higher prevalence of multimorbidity compared to those with 
GMFCS I–III (Table 2). There was also a higher odds of mul-
timorbidity among those with GMFCS levels IV–V compared 
to GMFCS levels I–III (OR: 3.45; 95% CI: 2.04–5.83). Only 
obesity (OR: 1.83; 95% CI: 1.01–1.20) was significantly 
associated with multimorbidity in individuals with CP.
Discussion
The principal findings of this study are that young adults with 
CP have a higher prevalence of NCDs relating to musculo-
skeletal, cardiometabolic, and pulmonary systems compared 
to the general population of young adults without CP. Age, 
being underweight or obese, smoking, and the level of motor 
impairment were each independently associated with higher 
odds of many NCDs and multimorbidity in young adults 
with CP.
Over the past few decades, global disease burden has 
shifted from premature death to years lived with disabilities, 
and from communicable diseases to NCDs.13 Nearly 40% of 
global NCD-related deaths occur before the age of 70 years.26 
Given the increased survival rate15 and a marginally increas-
ing prevalence of CP16 throughout the past several decades, 
there is an expanding adult CP population that is at risk for 
premature NCD-related deaths. In the current study, young 
adults with CP had a higher prevalence of multiple NCDs 
and a multimorbidity prevalence of nearly 25%. By middle 
age (40–60 years), adults with CP have a multimorbidity 
prevalence of nearly 60%,19 which is 1.5–2.9 times higher 
than the general population of middle-age adults.27 Collec-
tively, these data highlight a CP-specific NCD burden that 
is unique from the general population.
Musculoskeletal morbidity
The finding that young adults with CP have a high prevalence 
of musculoskeletal morbidities is clinically important, but 
not surprising. Children with CP have an underdeveloped 
musculoskeletal system,5,6 with deficits presenting as early as 
2 years old.28 Mobility deficits are observed as children with 
CP age into and throughout their adult years10–12 leading to 
a progressive loss of mechanical loading, which is an essen-
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Figure 1 Prevalence of morbidity score for adults with CP vs without CP, as well as for adults with CP with GMFCS levels I–III vs IV–V.
Note: Significant differences between adults with and without CP (*), and between GMFCS levels I–III vs IV–V (#); p<0.05.
Abbreviations: CP, cerebral palsy; GMFCS, Gross Motor Function Classification System.





Table 4 Multiple logistic regression models for independent predictors of multimorbidity
Model predictor(s) Odds ratio 95% CI p-value
Multimorbiditya Cerebral palsy Unadjusted 4.12 2.71–6.26 <0.001
Adjusted 2.67 1.69–4.23 <0.001
Age (years) 1.00 0.94–1.05 0.94
Sex (Ref: women) 1.14 0.77–1.68 0.51
Race (Ref: Non-Hispanic White) 0.94 0.78–1.13 0.50
BMI category (Ref: normal weight [BMI 18.5–24.9])
Underweight (BMI<18.5) 1.95 1.14–3.33 0.01
Overweight (BMI 25–29.9) 1.15 0.68–1.94 0.61
Obese (BMI≥30) 2.04 1.20–3.47 0.01
Smoking status (Ref: never smoked) 1.92 1.02–3.61 0.04
Note: a≥2 musculoskeletal, cardiometabolic, and pulmonary morbidities.
Abbreviations: BMI, body mass index; Ref, reference.
Table 3 Multiple logistic regression models for predictors of musculoskeletal, cardiometabolic, and pulmonary morbidities
Model predictor(s) Odds ratio 95% CI p-value
Musculoskeletal morbidity Cerebral palsy Unadjusted 10.10 6.77–15.1 <0.001
Adjusted 6.97 4.46–10.89 <0.001
Age (years) 1.09 1.03–1.14 <0.001
Sex (Ref: women) 0.88 0.62–1.26 0.48
Race (Ref: Non-Hispanic White) 0.86 0.72–1.02 0.08
BMI category (Ref: normal weight [BMI 18.5–24.9])
Underweight (BMI<18.5) 1.68 1.03–2.74 0.04
Overweight (BMI 25–29.9) 0.95 0.59–1.52 0.82
Obese (BMI≥30) 1.04 0.62–1.73 0.89
Smoking status (Ref: never smoked) 2.17 1.10–4.25 0.03
Cardiometabolic morbidity Cerebral palsy Unadjusted 2.84 1.89–4.26 <0.001
Adjusted 1.98 1.26–3.13 <0.01
Age (years) 1.05 0.99–1.11 0.14
Sex (Ref: women) 1.11 0.75–1.64 0.61
Race (Ref: Non-Hispanic White) 1.01 0.84–1.20 0.96
BMI category (Ref: normal weight [BMI 18.5–24.9])    
Underweight (BMI<18.5) 1.30 0.74–2.30 0.37
Overweight (BMI 25–29.9) 0.65 0.36–1.15 0.13
Obese (BMI≥30) 1.78 1.06–2.98 0.02
Smoking status (Ref: never smoked) 1.16 0.61–2.22 0.65
Pulmonary morbidity Cerebral palsy Unadjusted 1.36 1.01–1.84 0.04
Adjusted 1.11 0.78–1.58 0.56
Age (years) 0.97 0.92–1.02 0.17
Sex (Ref: women) 1.25 0.90–1.72 0.18
Race (Ref: Non-Hispanic White) 1.08 0.95–1.2 0.22
BMI category (Ref: normal weight [BMI 18.5–24.9])
Underweight (BMI<18.5) 1.15 0.69–1.93 0.58
Overweight (BMI 25–29.9) 1.06 0.71–1.59 0.78
Obese (BMI≥30) 1.26 0.79–2.00 0.32
Smoking status (Ref: never smoked) 1.42 1.02–1.97 0.04
Abbreviations: BMI, body mass index; Ref, reference.




NCD and multimorbidity in young adults with CP
Mobility deficits are also associated with musculoskeletal 
pain,10,12 which is inversely related to physical activity levels 
in those with CP.29 We found age to be a significant risk factor 
for musculoskeletal morbidity in the current study, suggest-
ing a worsening of musculoskeletal morbidity prevalence in 
those with CP even within a young and narrow age range.
Cardiometabolic morbidity
The progressive loss of function in persons with CP may 
help to explain why the risk for cardiometabolic morbidi-
ties is higher in young adults with CP.30,31 The prevalence of 
hypertension and hyperlipidemia in young adults with CP in 
the current study was 11.8% and 3%, respectively. Ryan et 
al32 showed that children and adolescents with CP, aged 6–17 
years, had a 10.5% prevalence of hypertension, with age being 
significantly and positively associated with blood pressure. 
Moreover, van der Slot et al33 reported a higher prevalence of 
hypertension of 25.6% in those with CP between the ages of 25 
and 45 years, while we have previously reported prevalences 
up to 50% in 40–60-year-olds for prehypertension and hyper-
tension.19 Ryan et al34 found a prevalence of hyperlipidemia 
of 27.3% in adults with CP aged 18–65 years, while 9% were 
taking medication for dyslipidemia and another 9% for hyper-
tension. Although the frequency reporting myocardial infarc-
tion was low in the CP cohort (2%) and absent in the adults 
without CP in the current study, the difference is still clinically 
meaningful given the young age of study participants. These 
findings suggest an early cardiovascular risk phenotype among 
individuals with CP, which provides insight as to why adults 
with CP have a substantially higher cardiovascular mortality 
rates compared to the general population.17 Taken together, 
the window to prevent cardiovascular complications in those 
with CP occurs prior to reaching adulthood.
Somewhat surprisingly, we did not see a difference in the 
prevalence of impaired glucose tolerance or type 2 diabetes, 
which is consistent with another study in adults with CP that 
found normal fasting glucose levels.34 However, a glucose 
challenge, such as a glucose tolerance test, may be more 
indicative of glucose handling, and has not been exclusively 
studied in those with CP. Elder et al35 reported that adults 
with spinal cord injury, a comparative reference population 
often used to better understand pathologies observed in 
CP,36,37 saw no differences in fasting glucose or insulin levels 
compared to individuals without CP. However, after admin-
istering a glucose load, both glucose and insulin levels were 
significantly elevated compared to individuals without CP, 
suggesting impaired glucose handling. Given the hallmark 
altered musculoskeletal5,6,38 and functional profiles5–7 in CP, 
both of which are associated with insulin resistance,30,31,35 it 
is curious as to why glucose dysregulation is not a prevalent 
complication in those with CP. This phenomenon requires 
further investigation; and yet, it may be a direct result of poor 
clinical screening for metabolic diseases in this population.
Pulmonary morbidity
Children with CP have poor cardiorespiratory fitness, which 
is associated with an increased cardiometabolic disease risk.8 
In addition, the low cardiorespiratory capacity in children 
with CP39 is linked to lower chest mobility during respira-
tion.40 It is of interest whether functional limitations in CP 
lead to pulmonary dysfunction and morbidity, or if pulmonary 
dysfunction and morbidity are drivers of the functional loss 
with age and subsequent increased risk for developing NCDs. 
Future research is needed to better understand the causal 
pathways leading to pulmonary dysfunction and morbidity 
in the context of disability severity.
The finding that modifiable risk factors, such as weight 
status and smoking status, are associated with NCDs and 
multimorbidity prevalence is consistent with our previous 
study in middle-age adults with CP.19 While there are known 
associations between NCDs and being underweight,41 being 
obese,42 and using tobacco,14 there are weight management 
and smoking cessation programs that may help to mitigate 
the high prevalence of NCDs observed in the adult CP 
population. Not surprisingly, motor impairment was also 
significantly associated with NCDs and multimorbidity in the 
current study. In general, adults with CP have lower levels 
of physical activity. However, the degree of physical activity 
restriction is inversely related to increasing levels of motor 
impairment.43 Poor diet or malnutrition, tobacco use, and 
physical inactivity are the three most common modifiable 
risk factors associated with NCD-related premature death.14 
These three modifiable risk factors are associated with NCDs 
and multimorbidity in the entire cohort of young adults with 
and without CP. Interestingly, young adults with CP had a 
fewer number of risk factors associated with musculoskeletal 
morbidity, pulmonary morbidity, and multimorbidity, but 
similar strength of associations, compared with the combined 
sample of young adults with and without CP. This may sug-
gest that those with CP have a unique set of risk factors for 
developing or accelerating NCDs compared with the general 
population. Future initiatives are needed to develop programs 
with goals specific to assist persons with CP and caregivers 
for maintaining a healthy body composition, abstinence from 
tobacco use, and improving sleep, nutrition, and physical 
activity levels.44






The study has several strengths. To date, this is the largest study 
in young adults with CP, which also includes a control group 
within the same age range. The recent initiatives in CP-specific 
surveillance programs have helped to identify a disease burden 
that is accelerated in the CP population by middle age.19 This 
has prompted the investigation of evaluating the NCD profiles 
in a younger cohort of adults with CP to help identify the win-
dow of disease clustering. Another strength of the current study 
is that all data were pulled from the same site (hospital system at 
the University of Michigan) and within a relatively narrow time 
period. This is important to consider because different global 
regions and time periods are associated with heterogeneous 
development of communicable diseases and NCDs.13
Several limitations must also be discussed. First, due to the 
design, we were unable to determine a cause and effect among 
exposures and outcomes. Second, we were limited to identify-
ing NCDs using medical records that yielded a dichotomous 
coding for NCDs rather than a graded scale. Therefore, the 
severity of conditions was not accessible, which could have 
provided further insight into the NCD profiles of young adults 
with CP (eg, bone mineral density or T-scores for osteopenia 
and osteoporosis). Another limitation is the accuracy of the 
medical charts. If the NCD was not diagnosed on their medical 
chart, the participant was considered to not have that NCD. 
However, screening for NCDs in young adults with CP is not a 
common clinical practice in the United States. Therefore, our 
estimates may actually be underrepresenting the true extent 
of the NCD risk in young adults with CP.
Conclusion
Young adults with CP have a high prevalence of NCDs and 
multimorbidity, particularly for the musculoskeletal and 
cardiometabolic systems. Modifiable risk factors, such as 
underweight, obesity, and smoking status, were associated 
with NCDs and multimorbidity. This is an important finding 
because adults with CP are not expected to have such a dis-
ease burden at a young age, and clinical screening has been 
inadequate. Our findings highlight the importance of clinical 
screening for NCD clustering in persons with CP as early as 
adolescence or young adulthood, and may prompt early behav-
ioral interventions for NCD prevention in this population.
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